Sage Competitors

Delisted . USA . 
Stock . Sage Therapeutics
SAGEDelisted Stock  USD 8.68  0.00  0.00%   
Sage Therapeutics competes with Invivyd, ARS Pharmaceuticals, Climb Bio, Sinovac Biotech, and Niagen Bioscience; as well as few others. The company conducts business under Biotechnology sector and is part of Health Care industry. Analyzing Sage Therapeutics competition allows you to expand the diversification possibilities of your existing portfolios and to get a better perspective on locking in new positions. Investors sometimes prefer comparable analysis of Sage Therapeutics to its intrinsic valuation because they are able to contrast its competitors on a relative basis. Check out World Market Map to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in price.

Sage Therapeutics vs Ikena Oncology Correlation

Poor diversification

The correlation between Sage Therapeutics and IKNA is 0.72 (i.e., Poor diversification) for selected investment horizon. Overlapping area represents the amount of risk that can be diversified away by holding Sage Therapeutics and IKNA in the same portfolio, assuming nothing else is changed.

Moving against Sage Stock

  0.87ORGN Origin MaterialsPairCorr
  0.67HPQ HP IncPairCorr
  0.5T ATT Inc Earnings Call TodayPairCorr
Specify up to 10 symbols:
Hype
Prediction
LowEstimatedHigh
8.688.688.68
Details
Intrinsic
Valuation
LowRealHigh
7.027.029.55
Details
Naive
Forecast
LowNextHigh
9.299.299.29
Details
Bollinger
Band Projection (param)
LowerMiddle BandUpper
8.578.999.41
Details
Please note, it is not enough to conduct a financial or market analysis of a single entity such as Sage Therapeutics. Your research has to be compared to or analyzed against Sage Therapeutics' peers to derive any actionable benefits. When done correctly, Sage Therapeutics' competitive analysis will give you plenty of quantitative and qualitative data to validate your investment decisions or develop an entirely new strategy toward taking a position in Sage Therapeutics.

Sage Therapeutics Competition Correlation Matrix

Typically, diversification allows investors to combine positions across different asset classes to reduce overall portfolio risk. Correlation between Sage Therapeutics and its competitors represents the degree of relationship between the price movements of corresponding delisted stocks. A correlation of about +1.0 implies that the price of Sage and its corresponding peer move in tandem. A correlation of -1.0 means that prices move in opposite directions. A correlation of close to zero suggests that the price movements of assets are uncorrelated; in other words, the historical price movement of Sage Therapeutics does not affect the price movement of the other competitor.

High positive correlations

CLYM
+ 0.86
RGLS
IKNA
+ 0.84
RGLS
SPRY
+ 0.83
RGLS
IKNA
+ 0.74
SPRY
IKNA
+ 0.74
CLYM
CLYM
+ 0.72
SPRY
  

High negative correlations

NAGE
- 0.77
RGLS
NAGE
- 0.71
CLYM
RVNC
- 0.65
RGLS
RVNC
- 0.62
IVVD
IKNA
- 0.6
NAGE
NAGE
- 0.53
SPRY

Risk-Adjusted Indicators

There is a big difference between Sage Stock performing well and Sage Therapeutics Company doing well as a business compared to the competition. There are so many exceptions to the norm that investors cannot definitively determine what's good or bad unless they analyze Sage Therapeutics' multiple risk-adjusted performance indicators across the competitive landscape. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.
Mean DeviationJensen AlphaSortino RatioTreynor RatioSemi DeviationExpected ShortfallPotential UpsideValue @RiskMaximum Drawdown
IVVD  4.98  0.00  0.03  0.00  5.64 
(5.53)
 11.11 
(8.57)
 46.37 
RGLS  6.78  3.67  0.97 (3.62) 1.47 
(8.24)
 15.42 
(5.33)
 140.81 
ITOS  0.39  0.00 (0.07) 0.20  0.43 
(0.55)
 1.09 
(0.79)
 3.17 
SPRY  3.96  0.16  0.06  0.09  4.50 
(4.68)
 8.29 
(8.73)
 32.13 
EXAI  0.00  0.00  0.00  0.00  0.00 
 0.00 
 0.00 
 0.00 
 0.00 
CLYM  5.97  1.63  0.26 (0.79) 5.29 
(7.31)
 14.49 
(8.38)
 42.56 
RVNC  3.04 (0.57) 0.00 (0.29) 0.00 
 0.00 
 6.38 
(5.97)
 40.39 
SVA  0.00  0.00  0.00  0.00  0.00 
 0.00 
 0.00 
 0.00 
 0.00 
NAGE  1.97 (0.42) 0.00 (0.24) 0.00 
 0.00 
 3.66 
(4.07)
 10.35 
IKNA  2.61  0.33  0.09 (3.22) 2.90 
(3.21)
 6.72 
(3.94)
 18.39 

Sage Therapeutics Competitive Analysis

The better you understand Sage Therapeutics competitors, the better chance you have of utilizing it as a position in your portfolios. From an individual investor's perspective, Sage Therapeutics' competitive analysis can cover a whole range of metrics. Some of these will be more critical depending on who you are as an investor and how you react to market volatility. However, if you are locking your investment sandscape to a long-term horizon, comparing the fundamental indicator across Sage Therapeutics' competition over several years is one of the best ways to analyze its investment potential.
    
 Better Than Average     
    
 Worse Than Peers    View Performance Chart
SAGE IVVD RGLS ITOS SPRY CLYM RVNC SVA NAGE IKNA
 0.00 
 8.68 
Sage
 2.13 
 1.84 
Invivyd
 0.12 
 8.16 
Regulus
 0.00 
 10.15 
Iteos
 1.58 
 9.99 
ARS
 6.77 
 5.05 
Climb
 0.00 
 3.65 
Revance
 0.00 
 6.47 
Sinovac
 1.23 
 5.61 
Niagen
 3.62 
 17.16 
Ikena
Market Volatility
(90 Days Market Risk)
Very steady
Very risky
Very steady
Very steady
Somewhat reliable
Risky
Very steady
Very steady
Somewhat reliable
Very steady
Market Performance
(90 Days Performance)
Weakest
Mild
Weakest
Weakest
Fair
Solid
Weakest
Weakest
Weakest
Weakest
Odds of Financial Distress
(Probability Of Bankruptcy)
Hazard
Moderate
Hazard
Hazard
Moderate
Fair
Hazard
Small
Tiny
Hazard
Current Valuation
(Equity Enterprise Value)
Over Valued
Under Valued
Over Valued
Over Valued
Under Valued
Under Valued
Over Valued
Fairly Valued
Under Valued
Over Valued
Buy or Sell Advice
(Average Analysts Consensus)
Not Available
Buy
Not Available
Not Available
Strong Buy
Strong Buy
Not Available
Not Available
Strong Buy
Not Available
Trade Advice
(90 Days Macroaxis Advice)
Not Rated
Strong Sell
Not Rated
Not Rated
Strong Sell
Strong Sell
Not Rated
Hold
Cautious Hold
Not Rated
Current Ratio
17.69
9.14
8.82
6.42
N/A
N/A
3.38
2.98
N/A
6.98
Net Asset
547.22 M
129.51 M
84.18 M
686.98 M
351.15 M
217.19 M
478.45 M
13.66 B
68.28 M
141.51 M
Profit Margin
N/A
-1.2
N/A
N/A
-0.56
N/A
-0.72
0.22
0.16
N/A
EBITDA
(409.49 M)
(173.76 M)
(45.85 M)
(121.82 M)
(3 M)
(30.36 M)
(290.64 M)
(6.03 M)
9.21 M
(48.59 M)
Operating Margin
-1.71
-0.84
N/A
N/A
-1.64
N/A
-0.54
0.42
0.12
N/A
Current Valuation
190.79 M
439.39 M
500.99 M
(61.62 M)
819.78 M
239.6 M
680.39 M
297.09 M
416.96 M
628.86 M
Price To Book
1.48
5.27
8.19
0.91
6.7
1.72
12.3
1.82
6.76
6.2
Retained Earnings
(2.97 B)
(901.99 M)
(559.57 M)
(9.78 M)
(123.31 M)
(229.88 M)
(2.08 B)
7.12 B
(181.91 M)
(331.62 M)
Current Asset
188.49 M
N/A
134.26 M
N/A
N/A
N/A
208.68 M
128.52 M
N/A
N/A
Beta
0.3
0.6
0.37
1.49
0.74
-0.15
0.95
0.0649
2.09
0.5
Number Of Employees
353
99
34
173
162
17
597
1.96 K
104
9
Shares Outstanding
62.78 M
281.99 M
69.23 M
44.21 M
98.85 M
47.74 M
104.39 M
99.29 M
79.81 M
41.89 M
Cash Flow From Operations
(267.19 M)
(170.49 M)
(41.67 M)
(98.18 M)
13.55 M
(15.56 M)
(216.57 M)
106.02 M
12.11 M
(46 M)
Annual Yield
N/A
N/A
N/A
N/A
N/A
N/A
N/A
8.5
N/A
N/A
Total Debt
11.84 M
1.3 M
274 K
5.1 M
42 K
532 K
478.43 M
298.98 M
2.65 M
7.52 M
Return On Equity
-0.6
-0.68
-0.54
-0.35
-0.46
-0.26
-20.97
0.25
0.39
-0.24
Return On Asset
-0.34
-0.26
-0.34
-0.18
-0.19
-0.17
-0.24
0.11
0.16
-0.18
Number Of Shares Shorted
2.22 M
21.41 M
2.09 M
2.06 M
20.22 M
1.8 M
4.51 M
82.76 K
5.8 M
168.63 K
Book Value Per Share
5.89
0.43
1.04
12.9
1.49
2.6
-1.55
7.52
0.88
28.82
Current Liabilities
15.31 M
N/A
12.63 M
N/A
N/A
N/A
17.52 M
58 M
N/A
N/A
Total Asset
547.22 M
129.51 M
84.18 M
686.98 M
351.15 M
217.19 M
478.45 M
13.66 B
68.28 M
141.51 M
Debt To Equity
0.01
0.004
0.17
0.007
N/A
N/A
2.94
0.28
N/A
0.036
Short Ratio
0.65
4.75
1.57
1.34
11.35
0.8
1.7
N/A
6.88
0.88
Target Price
8.58
10.0
7.0
10.35
28.0
9.5
9.47
3.52
15.8
276.0
Shares Owned By Institutions
83.59
75.04
82.87
90.28
88.45
43.34
87.45
32.02
40.59
76.2
Market Capitalization
544.94 M
490.66 M
564.95 M
448.68 M
1.02 B
322.51 M
381.02 M
642.44 M
486.02 M
718.82 M
Price To Earning
3.07
N/A
-0.69
50.5
N/A
N/A
-7.6
48.65
N/A
3.89
Price To Earnings To Growth
0.74
N/A
-0.04
N/A
N/A
N/A
-0.64
N/A
N/A
N/A
Price To Sales
7.74
9.81
7.43
12.78
7.13
N/A
1.48
1.83
3.9
43.56
Net Income
(400.67 M)
(169.93 M)
(46.36 M)
(134.41 M)
8 M
(73.9 M)
(323.99 M)
(258.36 M)
8.55 M
(49.23 M)
Earnings Per Share
-4.89
-0.45
-0.68
-4.73
-0.81
-0.59
-3.34
0.97
0.24
-7.68
Shares Owned By Insiders
10.36
11.28
2.7
0.34
16.82
0.79
8.55
51.42
34.0
8.0
Revenue
41.24 M
25.38 M
N/A
35 M
89.15 M
N/A
234.04 M
448.27 M
99.6 M
N/A
Working Capital
459.69 M
38.7 M
74.85 M
469.18 M
310.86 M
149.94 M
249.64 M
10.68 B
46.15 M
116.39 M
Cash And Equivalents
1.51 B
418.67 M
47.53 M
791.86 M
N/A
N/A
233.82 M
176.72 M
N/A
192.81 M
Cash Per Share
25.47
3.84
3.25
22.26
N/A
N/A
3.2
1.79
N/A
5.32
Gross Profit
(75.23 M)
46.71 M
(36.15 M)
N/A
114.87 M
N/A
103.69 M
443.44 M
79.68 M
(29.89 M)
Day Typical Price
8.68
1.82
8.14
10.15
9.99
5.01
3.65
6.47
5.61
17.08
Accumulation Distribution
N/A
0.0745
0.0134
N/A
N/A
0.19
N/A
N/A
N/A
0.0811
Market Facilitation Index
N/A
0.14
0.11
N/A
N/A
1.07
N/A
N/A
N/A
1.44
Daily Balance Of Power
0.0
(0.29)
0.0909
0.0
0
0.2991
0.0
0.0
0
0.4167
Period Momentum Indicator
N/A
(0.04)
0.01
N/A
(0.16)
0.32
N/A
N/A
(0.07)
0.6
Rate Of Daily Change
1.0
0.98
1.0
1.0
0.98
1.07
1.0
1.0
0.99
1.04
Day Median Price
8.68
1.81
8.13
10.15
9.99
4.98
3.65
6.47
5.61
17.04
Price Action Indicator
N/A
0.01
0.04
N/A
(0.08)
0.22
N/A
N/A
(0.04)
0.42
Relative Strength Index
55.24
44.55
76.38
49.72
48.68
59.6
54.56
N/A
37.37
56.09
Coefficient Of Variation
1816.42
3275.27
483.31
3829.2
1660.87
524.08
(1,353)
N/A
(725.59)
1037.44
Mean Deviation
1.96
4.98
6.78
0.3865
3.96
5.97
3.04
N/A
1.97
2.61
Jensen Alpha
0.281
N/A
3.67
0.004
0.1648
1.63
(0.57)
N/A
(0.42)
0.3335
Total Risk Alpha
(0.03)
(0.22)
2.6
(0.03)
(0.001)
1.07
(0.88)
N/A
(0.50)
0.123
Sortino Ratio
0.1038
0.0298
0.9741
(0.07)
0.059
0.2599
N/A
N/A
N/A
0.0881
Downside Variance
4.06
36.38
13.54
0.263
22.45
33.58
N/A
N/A
N/A
10.56
Standard Deviation
4.76
7.62
17.58
0.58
5.52
8.17
6.54
N/A
2.49
3.52
Kurtosis
46.7
6.02
52.45
2.23
2.15
2.5
15.23
N/A
(0.02)
1.61
Potential Upside
3.61
11.11
15.42
1.09
8.29
14.49
6.38
N/A
3.66
6.72
Treynor Ratio
(0.38)
N/A
(3.62)
0.1957
0.088
(0.79)
(0.29)
N/A
(0.24)
(3.22)
Maximum Drawdown
37.83
46.37
140.81
3.17
32.13
42.56
40.39
N/A
10.35
18.39
Variance
22.7
58.09
309.1
0.3364
30.49
66.73
42.72
N/A
6.18
12.38
Market Risk Adjusted Performance
(0.37)
N/A
(3.61)
0.2057
0.098
(0.78)
(0.28)
N/A
(0.23)
(3.21)
Risk Adjusted Performance
0.0489
0.0315
0.1615
0.0165
0.0529
0.1492
(0.05)
N/A
(0.09)
0.0787
Skewness
6.3
1.86
6.92
0.8396
0.721
1.28
(2.30)
N/A
0.1446
0.3701
Semi Deviation
1.7
5.64
1.47
0.4282
4.5
5.29
N/A
N/A
N/A
2.9
Information Ratio
0.0439
0.0236
0.2039
(0.07)
0.0506
0.1843
(0.08)
N/A
(0.16)
0.0813
Value At Risk
(3.48)
(8.57)
(5.33)
(0.79)
(8.73)
(8.38)
(5.97)
N/A
(4.07)
(3.94)
Expected Short fall
(2.63)
(5.53)
(8.24)
(0.55)
(4.68)
(7.31)
N/A
N/A
N/A
(3.21)
Downside Deviation
2.02
6.03
3.68
0.5128
4.74
5.79
N/A
N/A
N/A
3.25
Semi Variance
2.88
31.86
2.16
0.1833
20.24
27.95
N/A
N/A
N/A
8.4

Sage Therapeutics Competition Performance Charts

Five steps to successful analysis of Sage Therapeutics Competition

Sage Therapeutics' competitive analysis is the process of researching and evaluating its competitive landscape. It provides an understanding of the strengths, weaknesses, opportunities, and threats (SWOT) faced by Sage Therapeutics in relation to its competition. Sage Therapeutics' competition analysis typically involves several steps, including:
  • Identifying the key players in the market: This involves identifying the major competitors of Sage Therapeutics in the market, both direct and indirect, as well as new entrants and disruptive technologies.
  • Assessing the strengths and weaknesses of each competitor: This involves evaluating each competitor's strengths and weaknesses in areas such as product offerings, market share, brand recognition, financial performance, and distribution channels.
  • Understanding the competitive environment: This involves evaluating the regulatory environment, economic conditions, and other factors that may impact Sage Therapeutics' competitive landscape.
  • Identifying opportunities and threats: This involves using the information gathered during the analysis to identify opportunities and threats to Sage Therapeutics, and developing a strategy to address them.
  • Evaluating the competitive landscape: This involves understanding the competitive dynamics of the market, such as pricing, marketing, and distribution strategies, as well as analyzing the competitive advantage of each competitor.
Competitive analysis is an essential tool for businesses to stay ahead of the competition and can be used to inform decision-making and strategy development. By understanding the competitive landscape and staying informed about the activities of competitors, a company can make more informed decisions and improve its overall performance.

Complement your Sage Therapeutics position

In addition to having Sage Therapeutics in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run Utilities Thematic Idea Now

Utilities
Utilities Theme
Highly leveraged corporations that deliver utilities such as power, water or gas to public or business. The Utilities theme has 30 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Utilities Theme or any other thematic opportunities.
View All  Next Launch
Check out World Market Map to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in price.
You can also try the Instant Ratings module to determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance.

Other Consideration for investing in Sage Stock

If you are still planning to invest in Sage Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Sage Therapeutics' history and understand the potential risks before investing.
Transaction History
View history of all your transactions and understand their impact on performance
Fundamental Analysis
View fundamental data based on most recent published financial statements
Price Ceiling Movement
Calculate and plot Price Ceiling Movement for different equity instruments
Portfolio Optimization
Compute new portfolio that will generate highest expected return given your specified tolerance for risk
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2026 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY